Fig. 1

Change from baseline in trough FEV₁ at Week 24 by baseline SABA use^a. CFB change from baseline, CI confidence interval, FEV₁ forced expiratory volume in 1 s, LS least squares, SABA short-acting β₂-agonist, SAL salmeterol, UMEC umeclidinium, VI vilanterol. ^aMean SABA use was 3.91 puffs/day and 0.39 puffs/day in the high and low SABA use subgroups, respectively